RxDoctor Payments Data

John Cooke

Cardiovascular Disease · Stanford, CANPI 1902932155

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,000 of the $1,234 with a category attached, or 81.1%. Pfizer accounts for 81.1% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.

$1,234in general payments, 2019–2025

Across 5 payments — averaging $246.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Biotronik Inc.$117
  • AbbVie$117
$1,227,974in research payments, 2019–2025

Across 3 payments — averaging $409,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Avita Medical Americas, LLC$1.2M

What the payments were for

  • Consulting fees$1,00081%
  • Food & beverage$23419%

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$1,000
Biotronik Inc.3$117
AbbVie1$117

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,234 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Other cardiovascular disease in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →